Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

News Conference News AHA 2020

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

November 17, 2020

News Features

Playing With Heart: Returning Kids Safely to Sport in the COVID-19 Era

November 02, 2020

Echo Aids Diagnosis, Risk Prediction in Severe COVID-19

News Daily News

Echo Aids Diagnosis, Risk Prediction in Severe COVID-19

October 26, 2020

‘Message Unchanged,’ Say Researchers of Criticized COVID-19 CMR Study

News Daily News

‘Message Unchanged,’ Say Researchers of Criticized COVID-19 CMR Study

Michael O'Riordan

August 26, 2020

Influenza and Acute CV Events Can Go Hand in Hand

News Daily News

Influenza and Acute CV Events Can Go Hand in Hand

August 25, 2020

Signs of Cardiac Damage Even in Younger, Nonhospitalized COVID-19 Patients

News Daily News

Signs of Cardiac Damage Even in Younger, Nonhospitalized COVID-19 Patients

July 29, 2020

Latest Kawasaki Series Offers Clues to COVID-19 in Kids as Debate Persists

News Daily News

Latest Kawasaki Series Offers Clues to COVID-19 in Kids as Debate Persists

May 14, 2020

Don’t Overlook COVID-19’s Cardiovascular Footprint, Say NYC Physicians

News Daily News

Don’t Overlook COVID-19’s Cardiovascular Footprint, Say NYC Physicians

April 09, 2020

Missed Opportunities: Many HF Patients Not Tested for CAD

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

March 20, 2020

A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out

News Opinion Editor's Corner

A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out

March 16, 2020

News Opinion Editor's Corner

COVID-19 and the Heart: Insights From the Front Lines

March 12, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.